In this prospective single-institution study, functional status trajectory one year after intervention was compared for transcatheter (TAVR) versus surgical aortic valve replacement (SAVR). A moderate/large decline compared to preintervention status occurred in 23% of TAVR patients and 4% of SAVR patients. A frailty index, postoperative delirium, a
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Transcatheter
February 6, 2019
January 18, 2019
Patient Care and General Interest
Air pollution tops the World Health Organization’s list of Top 10 threats to global health.
January 11, 2019
Patient Care and General Interest
Ireland’s Cabinet is expected to consider opt-out organ donation legislation this spring.
January 10, 2019
Loghin and Loghin detail the intricacies of imaging modalities available for the assessment of patients in the era of novel mitral technologies. They include a description of functional mitral valve anatomy and discuss the multimodel approach to evaluation of patients undergoing implantation of transcatheter devices.
January 4, 2019
Edwards Lifesciences announced that the SAPIEN 3 Ultra system has received US Food and Drug Administration approval for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients who are determined to be at intermediate or greater risk of open-heart surgery.
January 2, 2019
Loger and colleagues implanted transcatheter prostheses in the mitral valve position in 33 pigs. Valve performance and heart function were analyzed for both supra-annular and subvalvular fixation.
December 18, 2018
The authors, using the STS/ACC TVT Registry, analyzed the the occurrence of patient-prosthesis mismatch (PPM) in 62,215 patients enrolled between 2014 and 2017. They found that severe and moderate PPM occurred in 12% and 25% of patients, respectively.
December 18, 2018
This study analyzed the cost-effectiveness of TAVR versus SAVR in 3110 intermediate-risk aortic stenosis patients from the PARTNER-2 trial. Using a Markov model, the authors found that TAVR is economically dominant from the perspective of lifetime cost-effectiveness in the US healthcare system.
December 14, 2018
Patient Care and General Interest
Truly remote percutaneous coronary intervention was performed in five human patients at Apex Heart Institute in Ahmedabad, India.
December 10, 2018
Basra and colleagues report that among patients with bioprosthetic aortic valves who had clinical or echocardiographic indications suggestive of leaflet thrombosis, one-third of patients had this diagnosis confirmed by four-dimensional computed tomography (4DCT).